{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:10:12Z","timestamp":1759896612980,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"DOI":"10.7759\/cureus.94070","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:50:11Z","timestamp":1759895411000},"source":"Crossref","is-referenced-by-count":0,"title":["Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management"],"prefix":"10.7759","author":[{"given":"Nirjhar","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn M","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasma","family":"Harindhanavudhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalamar D","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Billington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M","family":"Bomberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Bramante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960-1962 through 2017-2018","author":"Fryar CD","year":"2020","unstructured":"Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960-1962 through 2017-2018. NCHS Health E-Stats. 2020,","journal-title":"NCHS Health E-Stats"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing RR","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, et al.. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013, 369:145-54. 10.1056\/NEJMoa1212914","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"Prescription medications to treat overweight & obesity. (2024). Accessed. 1\/5\/2025: https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/prescription-medications-treat-overweight-obesity."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S95299","article-title":"Off-label drugs for weight management","volume":"10","author":"Hendricks EJ","year":"2017","unstructured":"Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017, 10:223-34. 10.2147\/DMSO.S95299","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref5","article-title":"Obesity in adults: drug therapy","author":"Perreault L","year":"2025","unstructured":"Perreault L. Obesity in adults: drug therapy. UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2211120","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Dekker TJ","year":"2022","unstructured":"Dekker TJ. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:1433. 10.1056\/NEJMc2211120","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg D","year":"2022","unstructured":"Eisenberg D, Shikora SA, Aarts E, et al.. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022, 18:1345-56. 10.1016\/j.soard.2022.08.013","journal-title":"Surg Obes Relat Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.0087","article-title":"Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study","volume":"155","author":"McTigue KM","year":"2020","unstructured":"McTigue KM, Wellman R, Nauman E, et al.. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 2020, 155:e200087. 10.1001\/jamasurg.2020.0087","journal-title":"JAMA Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14231","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity","volume":"322","author":"Aminian A","year":"2019","unstructured":"Aminian A, Zajichek A, Arterburn DE, et al.. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019, 322:1271-82. 10.1001\/jama.2019.14231","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2012.12.019","article-title":"Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus","volume":"216","author":"Johnson BL","year":"2013","unstructured":"Johnson BL, Blackhurst DW, Latham BB, et al.. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013, 216:545-56; discussion 556-8. 10.1016\/j.jamcollsurg.2012.12.019","journal-title":"J Am Coll Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005126","article-title":"Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure","volume":"6","author":"Benotti PN","year":"2017","unstructured":"Benotti PN, Wood GC, Carey DJ, et al.. Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure. J Am Heart Assoc. 2017, 6:e005126. 10.1161\/JAHA.116.005126","journal-title":"J Am Heart Assoc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056742","article-title":"Cardiovascular outcomes trials for weight loss interventions: another tool for cardiovascular prevention?","volume":"144","author":"Neeland IJ","year":"2021","unstructured":"Neeland IJ, McGuire DK, Sattar N. Cardiovascular outcomes trials for weight loss interventions: another tool for cardiovascular prevention?. Circulation. 2021, 144:1359-61. 10.1161\/CIRCULATIONAHA.121.056742","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MM, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13326","article-title":"Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review","volume":"22","author":"Ahmad NN","year":"2021","unstructured":"Ahmad NN, Robinson S, Kennedy-Martin T, Poon JL, Kan H. Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review. Obes Rev. 2021, 22:e13326. 10.1111\/obr.13326","journal-title":"Obes Rev"},{"key":"ref17","unstructured":"ICD-10-CM. (2024). Accessed. 2025: https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm\/index.html."},{"key":"ref18","unstructured":"International Classification of Diseases,Ninth Revision, Clinical Modification (ICD-9-CM). (2021). Accessed. 2025: https:\/\/archive.cdc.gov\/www_cdc_gov\/nchs\/icd\/icd9cm.htm."},{"key":"ref19","unstructured":"CPT\u00ae. (2024). Accessed. 2025: https:\/\/www.ama-assn.org\/practice-management\/cpt."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2057","article-title":"Predicting 10-year risk of end-organ complications of type 2 diabetes with and without metabolic surgery: a machine learning approach","volume":"43","author":"Aminian A","year":"2020","unstructured":"Aminian A, Zajichek A, Arterburn DE, et al.. Predicting 10-year risk of end-organ complications of type 2 diabetes with and without metabolic surgery: a machine learning approach. Diabetes Care. 2020, 43:852-9. 10.2337\/dc19-2057","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.0.0319","article-title":"Screening, referral, and participation in a weight management program implemented in five CHCs","volume":"21","author":"Clark D","year":"2010","unstructured":"Clark D, Chrysler L, Perkins A, Keith NR, Willis DR, Abernathy G, Smith F. Screening, referral, and participation in a weight management program implemented in five CHCs. J Health Care Poor Underserved. 2010, 21:617-28. 10.1353\/hpu.0.0319","journal-title":"J Health Care Poor Underserved"},{"key":"ref22","unstructured":"The R Project for Statistical Computing. (2025). Accessed. 1\/5\/2025: https:\/\/www.R-project.org\/."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004369","article-title":"How much weight loss is required for cardiovascular benefits? Insights from a metabolic surgery matched-cohort study","volume":"272","author":"Aminian A","year":"2020","unstructured":"Aminian A, Zajichek A, Tu C, et al.. How much weight loss is required for cardiovascular benefits? Insights from a metabolic surgery matched-cohort study. Ann Surg. 2020, 272:639-45. 10.1097\/SLA.0000000000004369","journal-title":"Ann Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman RR","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al.. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017, 377:1228-39. 10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001277","article-title":"Weight loss for patients with obesity: an analysis of long-term electronic health record data","volume":"58","author":"Liu N","year":"2020","unstructured":"Liu N, Birstler J, Venkatesh M, Hanrahan LP, Chen G, Funk LM. Weight loss for patients with obesity: an analysis of long-term electronic health record data. Med Care. 2020, 58:265-72. 10.1097\/MLR.0000000000001277","journal-title":"Med Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.3763","article-title":"Potential biases in machine learning algorithms using electronic health record data","volume":"178","author":"Gianfrancesco MA","year":"2018","unstructured":"Gianfrancesco MA, Tamang S, Yazdany J, Schmajuk G. Potential biases in machine learning algorithms using electronic health record data. JAMA Intern Med. 2018, 178:1544-7. 10.1001\/jamainternmed.2018.3763","journal-title":"JAMA Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.5867","article-title":"Frequency and types of patient-reported errors in electronic health record ambulatory care notes","volume":"3","author":"Bell SK","year":"2020","unstructured":"Bell SK, Delbanco T, Elmore JG, et al.. Frequency and types of patient-reported errors in electronic health record ambulatory care notes. JAMA Netw Open. 2020, 3:e205867. 10.1001\/jamanetworkopen.2020.5867","journal-title":"JAMA Netw Open"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21037\/atm-2022-54","article-title":"Does race\/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes?-a comparison between Asian versus White patients","volume":"10","author":"Scheen AJ","year":"2022","unstructured":"Scheen AJ. Does race\/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes?-a comparison between Asian versus White patients. Ann Transl Med. 2022, 10:1418. 10.21037\/atm-2022-54","journal-title":"Ann Transl Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky ER","year":"2024","unstructured":"Hankosky ER, Wang H, Neff LM, et al.. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024, 26:319-28. 10.1111\/dom.15318","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang MH","year":"2024","unstructured":"Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024, 7:e2427258. 10.1001\/jamanetworkopen.2024.27258","journal-title":"JAMA Netw Open"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01280-6","article-title":"Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial","volume":"400","author":"Abu Dayyeh BK","year":"2022","unstructured":"Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al.. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022, 400:441-51. 10.1016\/S0140-6736(22)01280-6","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.09.055","article-title":"Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity","volume":"19","author":"Sharaiha RZ","year":"2021","unstructured":"Sharaiha RZ, Hajifathalian K, Kumar R, et al.. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol. 2021, 19:1051-1057.e2. 10.1016\/j.cgh.2020.09.055","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06747-4","article-title":"Impact of endoscopic sleeve gastroplasty in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"33","author":"Nunes BC","year":"2023","unstructured":"Nunes BC, de Moura DT, Kum AS, et al.. Impact of endoscopic sleeve gastroplasty in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Obes Surg. 2023, 33:2917-26. 10.1007\/s11695-023-06747-4","journal-title":"Obes Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/387014-major-adverse-cardiovascular-event-outcomes-in-patients-with-obesity-and-type-2-diabetes-undergoing-medical-weight-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:50:16Z","timestamp":1759895416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/387014-major-adverse-cardiovascular-event-outcomes-in-patients-with-obesity-and-type-2-diabetes-undergoing-medical-weight-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.94070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}